Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome by Pentheroudakis, George et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2009, Article ID 854127, 10 pages
doi:10.1155/2009/854127
Research Article
Transcriptional Activity of Human EpidermalGrowth Factor
ReceptorFamilyandAngiogenesisEffectorsinLocoregionally
RecurrentHead andNeckSquamous CellCarcinoma and
Correlation with Patient Outcome
George Pentheroudakis,1 Nikolaos Angouridakis,2 Ralph Wirtz,3 Angelos Nikolaou,2
Konstantine T. Kalogeras,4,5 Nicholas Pavlidis,1 andGeorge Fountzilas5
1Department of Medical Oncology, Ioannina University Hospital, Ioannina 45500, Greece
2ENT Department, “AHEPA” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki 57100, Greece
3Siemens Healthcare Diagnostics, Cologne, Germany
4Hellenic Cooperative Oncology Group, Data Oﬃce, Athens 45118, Greece
5Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine,
Thessaloniki 57100, Greece
Correspondence should be addressed to George Pentheroudakis, gpenther@otenet.gr
Received 7 February 2009; Revised 11 June 2009; Accepted 23 July 2009
Recommended by Amanda Psyrri
Locoregional recurrence is the most common failure pattern in patients with head and neck squamous cell carcinoma (HNSCC).
Weretrospectivelyidentiﬁed41HNSCCpatientswithlocoregionalrelapseandusedkineticreversetranscription-polymerasechain
reaction (kRT-PCR) in order to study fresh-frozen tumour messenger RNA (mRNA) levels of the Human Epidermal growth factor
family members HER1-4, the Vascular Endothelial Growth Factors (VEGFs) A, B, C, D, and their receptors VEGFR1, 2, 3. High
VEGF-C and VEGFR3 tumour mRNA expression correlated with relapse beyond the primary locus (neck nodes or soft tissues,
P<. 05). Tumours with regional nodal involvement at diagnosis more often exhibited high transcriptional activity of VEGFR1
and VEGFR3 at the time of relapse (P<. 05). At a median follow-up of 52 months from the time of locoregional recurrence,
patients with high VEGF-C tumours at relapse had signiﬁcantly poorer postrelapse progression-free survival (R-PFS, 5 versus 47
months, log-rank P = .052) and a trend for inferior postrelapse overall survival (R-OS, 22 versus 44 months, log-rank P = .076)
in comparison to low VEGF-C tumours. Similar association with dismal outcome was seen for its receptor, VEGFR3 tumoural
mRNA levels (log-rank P = .060). In contrast, suppressed tumour transcription of VEGF-D was associated with poorer post-
relapse survival, though statistical signiﬁcance was not reached. Active transcription of the VEGF-C/VEGFR3 axis in recurrent
HNSCC is associated with failure at neck soft tissues/lymph nodes and inferior survival post-relapse.
Copyright © 2009 George Pentheroudakis et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Locoregional recurrence is the most common pattern of
failure after deﬁnitive treatment of head and neck squamous
cellcarcinoma(HNSCC),despiteincreasinguseofcombined
modality approaches incorporating chemotherapy, radio-
therapy, and surgery as initial management of patients with
locally advanced tumours [1]. Failure to achieve control
of locoregional disease increases the likelihood of distant
metastases and compromises patient survival and quality
of life. Even in patients succumbing to distant metastatic
disease, uncontrolled cancer at the primary site or neck is
seen in 90% of the cases [2]. In several large series and
multi-institutional trials, the rate of locoregional relapse
ranged from 20% to 57%, the most important predictors
for failure being involved resection margins, regional nodal
metastases, advanced T stage, high grade, neurogenic/vessel
invasion, and p53 gene mutations [3]. In the occurrence of2 Journal of Oncology
isolated locoregional recurrence, long-term disease control is
achievedinaminorityofpatients(10%–25%),namely,those
able to undergo surgical salvage and/or re-irradiation. Clin-
icopathological parameters that predict outcome of patients
with HNSCC locoregional recurrence have been reported in
a number of studies and included time interval from diagno-
sistorelapse,bulk,site,andresectabilityofrecurrence,ability
to re-irradiate at doses >60Gy, and performance status [4,
5]. However, no data are available on molecular tumour
biomarkers of potential prognostic/predictive signiﬁcance
for the outcome of patients with locoregionally recurrent
HNSCC. Several investigators have reported overexpression
of Human Epidermal growth factor Receptor (HER) family
members and active angiogenic activity in HNSCC, with
important implications since therapeutic compounds target-
ingthesecellularpathwaysareavailable.Inviewoftheabove,
we studied the tumour transcriptional activity of HER and
vascularendothelialgrowthfactor(VEGF/VEGFR)pathways
at the occurrence of locoregional recurrence, retrospectively
examined associations with clinicopathological characteris-
tics and analyzed their utility for predicting patient outcome
following relapse.
2. Patientsand Methods
Patients with localized stage I-III HNSCC managed between
January2002andAugust2004attheENTDepartmentofthe
Aristotle University of Thessaloniki with potentially curative
surgery and/or radical external beam irradiation and subse-
quently experiencing isolated locoregional recurrence were
retrospectively identiﬁed. Isolated locoregional recurrence
was deﬁned as one occurring in the primary site, neck nodes
or neck soft tissues in the absence of distant metastases. This
constitutedthecriterionforpatientidentiﬁcationandforthe
studyofHER/VEGFpathwaysinfreshtumourtissuebiopsies
obtained at the time of locoregional recurrence and snap-
frozen at −80
◦C. A waiver of consent for the use of biologic
material was provided by the Bioethics Committee of the
Aristotle University of Thessaloniki.
Intact RNA of high quality as determined by analysis of
the housekeeping gene RPL37A was isolated from 41 fresh-
frozen tumour tissue samples with tumour cellularity of
at least 70%. Approximately 50mg of fresh-frozen tumor
tissuewerecrushedinliquidnitrogen.RLT-Buﬀer(QIAGEN,
Hilden, Germany) was added and the homogenate was
centrifuged through a QIAshredder column (QIAGEN).
From the eluate, total RNA was isolated using the RNeasy
Kit (QIAGEN) according to the manufacturer’s instructions.
RNA yield was determined by UV absorbance, and RNA
quality was assessed by analysis of ribosomal RNA band
integrity on an Agilent 2100 Bioanalyzer RNA 6000 LabChip
kit (Agilent Technologies, Palo Alto, CA). Kinetic reverse
transcription-polymerase chain reaction (kRT-PCR) was
applied for the assessment of messenger RNA (mRNA)
expression of HER1 (EGFR), HER2, HER3, HER4, VEGF-A
(allisoforms),VEGF-B,VEGF-C,VEGF-D,VEGFR1(FLT1),
VEGFR2 (KDR), and VEGFR3 (FLT4) using the following
TaqMan-based primer/probe sets:
VEGF-A Probe CACCATGCAGATTATGCGGATCAA-
ACCT
Forward Primer GCCCACTGAGGAGTCCAACA
Reverse Primer TCCTATGTGCTGGCCTTGGT
VEGF-B Probe CACATCTATCCATGACACCACTTTCCT-
CTGG
Forward Primer TGGCAGGTAGCGCGAGTAT
Reverse Primer CCCTGTCTCCCAGCCTGAT
VEGF-C Probe TTGAGTCATCTCCAGCATCCGAGGAAA
Forward Primer CCACAGATGTCATGGAATCCAT
Reverse Primer TGCCTGGCTCAGGAAGATTT
VEGF-D Probe TGACATTGAAACACTAAAAGTTATAGA-
TGAAGAATGGCA
Forward Primer ACTAGGTTTGCGGCAACTTTCT
Reverse Primer TCTCTAGGGCTGCACTGAGTTCT
FLT1 Probe TGCTGTCGCCCTGGTAGTCATCAAACA
Forward Primer CATGGGAGAGGCCAACAGA
Reverse Primer AACCTTTGAAGAACTTTTACCGAATG
KDR Probe TCTTGGCATCGCGAAAGTGTATCCACA
Forward Primer TTCCAAGTGGCTAAGGGCAT
Reverse Primer CGTGCCGCCAGGTCC
FLT4 Probe TGCCTGCTTCCCTGGGTAGTCCC
Forward Primer GCACCCACTTACCCCGC
Reverse Primer GAGTTTAACTCAGGTGTCACCTTTGA
Forty cycles of ampliﬁcation were applied, and the cycle
threshold (CT) values of the target genes were identiﬁed. CT
values were normalized by subtracting the CT value of the
housekeeping gene RPL37A from the CT value of the target
gene (ΔCT). RNA results were then reported as 40-ΔCT
values, which would correlate proportionally to the mRNA
expression level of the target gene. Human reference total
RNA pooled from ten human cell lines (Stratagene, La Jolla,
CA) was used as a positive control. RNA-free DNA extracted
from tumor tissues was used as a negative control.
We sought to study the distribution of biomarker values,
the correlation of biomarkers to various clinicopathological
parameters at ﬁrst diagnosis and at the time of recurrence,
the association of biomarkers with time from diagnosis
to relapse (relapse-free interval, RFI), and their predictive
signiﬁcance for relapse-related progression-free survival (R-
PFS) and overall survival (R-OS). RFI was measured from
initial diagnosis until the time of isolated locoregional
recurrence, R-PFS from the time of isolated locoregional
relapse until veriﬁed disease progression, and death or last
contact and R-OS from locoregional relapse until death from
any cause or date of last contact. Disease progression (R-PFS
event) was considered to be an increase in tumour maximal
diameter of >20% or appearance of new lesions despite
salvage therapy. Both R-OS and R-PFS were estimated using
the Kaplan-Meier product-limit method, and comparisons
were performed using the log-rank test.
Categorical data were presented as counts and corre-
sponding percentages, while the continuous variables were
summarized using the medians and ranges. Distributional
studies of gene mRNA expression values conﬁrmed the
absence of natural cut-oﬀs in frequency histograms, while
the small sample size further supported the use of the
median as the optimal cut-oﬀ. Gene mRNA expression was
considered low or negative when below the median of allJournal of Oncology 3
measured mRNA values and high or positive when above the
median and was used as a categorical variable in the analysis.
Comparisons between mRNA expression and categorical
variables were performed using the Fisher’s exact test. The
level of signiﬁcance for all statistical tests was α = 0.05.
AnalysiswasconductedusingtheSPPSforWindows,version
15.
3. Results
3.1. Clinicopathological Characteristics. Forty-one male
patients, mostly heavy smokers and consumers of alcohol,
initially presented at a median age of 65 with hoarseness and
dysphagia. Diagnostic work-up led to diagnosis of squamous
cell carcinoma of the larynx predominantly (90% of cases),
mostly stage T1-3 (88% of cases), more often node-negative
(85%), and moderately-well to well diﬀerentiated (61%).
Initial management consisted of surgical resection of the
tumour by either local excision (24%), segmental (19%), or
total (24%) laryngectomy, whereas in one-third of the cases
only a bioptic procedure was done and radical external beam
radiotherapy was administered. Adjuvant chemotherapy
was not administered, with the exception of one patient.
Locoregional relapse occurred after a median of 15 months
in the primary site (66%), neck lymph nodes (15%), or neck
soft tissues (19%) and was managed by means of surgical
resection (65% of patients) and/or irradiation (24%) and
chemotherapy (24%). At the time of relapse, 46% of patients
were managed with surgery only and 19% with resection
followed by irradiation or chemotherapy. Among the 24%
of patients who received radiotherapy at relapse, 17%
had external beam radiotherapy only and 7% concurrent
chemoradiation. No patients received re-irradiation. Among
ﬁve patients who had chemotherapy administered and
available data, three were treated with paclitaxel/liposomal
doxorubicin, one with paclitaxel/gemcitabine, and one with
weekly methotrexate. Clinicopathological characteristics at
ﬁrst diagnosis and at locoregional relapse are summarised in
Table 1.
3.2. Association of Biomarkers with Clinicopathological
Parameters. High versus low mRNA expression of HER1-4
genes, VEGF-A, B, C, D genes, and receptors VEGFR1, R2,
R3 were examined for associations with alcohol consump-
tion, tobacco consumption, age, and nodal status at initial
diagnosis,relapse-freeinterval,site,size,andgradeatrelapse.
High VEGF-C transcription correlated signiﬁcantly with
tropismforrelapsebeyondtheprimarysite:50%ofrelapsing
patients with high tumoural VEGF-C mRNA expression
relapsed in lymph nodes or soft tissues versus only 15%
of those who harboured tumours with low VEGF-C (test,
P = .009). The same association was observed for tumoural
transcription of VEGFR3 and the receptor of VEGF-C:
tumours with high mRNA expression of VEGFR3 relapsed
in neck nodes or soft tissues in 53% of the recurrent cases,
while those with low expression relapsed in only 10% (P =
.017). Tumoural VEGF-C/VEGFR3 mRNA expression may
be a marker of predilection for relapse in regional lymph
nodes/soft tissues rather than the primary site.
Tumours with regional nodal involvement at diagno-
sis more often exhibited high transcriptional activity of
VEGFR1 or VEGFR3 at the time of relapse (test, P<. 05).
Among tumours proﬁled with high mRNA expression of
VEGFR1 or VEGFR3 at relapse, regional nodal involvement
had occurred in approximately 20% of the cases at initial
presentation. In sharp contrast, no nodal metastases had
been present at initial diagnosis in cases where tumoural
VEGFR1 or VEGFR3 mRNA expression at relapse was low.
This preliminary ﬁnding deserves further investigation, as it
appears that proﬁling of VEGFR1 and VEGFR3 in HNSCC
patients at initial diagnosis may be of potential value for
predicting nodal involvement or locoregional relapse.
In addition, a trend was found for high VEGFR1
tumoural expression at relapse to be associated with tropism
for nodal or soft tissue failure (test, P = .056), and for
high VEGF-B with a history of high alcohol consumption
(P = .075). No other clinically or statistically signiﬁcant
associations of studied biomarkers with clinicopathological
charact eristicswer eseen.Table 2 summarizesthebiomarkers
with the most signiﬁcant associations with clinicopathologi-
cal data, while all associations of the HER family genes with
clinicopathological data are shown in Table 3.
3.3.PredictiveSigniﬁcanceforRFI. Transcriptionalactivityof
anyofthestudiedbiomarkerswasnotsigniﬁcantlyassociated
with occurrence of early or late locoregional relapse (RFI of
less versus more than 12 months). Moreover, transcription
of the studied biomarkers could not predict the timing of
relapse, even when the latter was examined as a continuous
time variable (Mann-Whitney U test, P>0.1).
3.4. Predictive Signiﬁcance for R-PFS. At a median follow-
up of 52 months from the time of locoregional recurrence
(range 8–53 months), transcriptional activity of HER and
VEGF/VEGFR family members was examined for predictive
signiﬁcance for survival from relapse until progression or
death (R-PFS). High mRNA expression of VEGF-C in the
tumour at the time of locoregional recurrence was signiﬁ-
cantly associated with shorter progression-free survival (log-
rank, P = .052). Patients who harboured tumours with
low VEGF-C mRNA expression had a median R-PFS of 47
months versus a median R-PFS of only 5 months for the
patients with tumours expressing high VEGF-C (Figure 1).
Moreover, mRNA expression levels of its receptor, VEGFR3,
were related to patient outcome with a trend for statistical
signiﬁcance (log-rank, P = .060). Patients with high tumour
transcription of VEGFR3 at relapse reached a median R-PFS
of only 12 months, in contrast to those harbouring tumours
with low VEGFR3 mRNA expression, in whom the median
R-PFS had not been reached yet at the time of the analysis
(Figure 2). An association of tumour VEGF-D expression
and R-PFS was speculated, though no statistical signiﬁcance
was observed (log-rank, P = 0.41). Low tumour VEGF-D
mRNA expression was associated with a median R-PFS of4 Journal of Oncology
Table 1: Clinicopathological characteristics at initial diagnosis and locoregional relapse.
N = 41
At diagnosis At recurrence
Age
Median (range) 65 (45–77)
Relapse-free interval (months)
Median (range) 15 (5–221)
Size (cm)
Median (range) 2 (0.3–6) 2.6 (0.6–10)
N % N %
Gender
Male 41 100
Family history
No 29 71
Yes 12 29
Smoking history
No 2 5 28 68
Yes 39 95 13 32
Pack years
Median (range) 52.5 (0–125)
Alcohol consumption
Low 13 32
Moderate 16 39
High 12 29
Symptoms
Hoarseness 26 63
Dyshphagia 10 24
Dyspnoea 1 2
Sore mouth 2 5
Ulceration 1 2
Lymphadenopathy 1 2
Primary site
Glottic 26 63
Supraglottic 10 24
Transglottic 1 2
Oropharynx 3 7
Unknown primary 1 2
Site of recurrence
Local 27 66
Lymph nodes ± local 61 5
Other 81 9
Ts t a g e
T1 16 39
T2 12 29
T3 8 20
T4 4 10
Unknown 1 2
Ns t a g e
N0 35 85
N1 3 7
N2 1 2
Unknown 2 5Journal of Oncology 5
Table 1: Continued.
N = 41
At diagnosis At recurrence
Grade
I7 1 7 9 2 2
II 18 44 16 39
III 5 12 7 17
I V 1225
I n S i t u 1200
V e r r u c o u s 1212
Unknown 8 20 6 15
Surgery
Biopsy 13 32 14 34
Total laryngectomy ± nodal resection 10 24 19 46
Hemilaryngectomy or segmental resection 8 19 1 2
Local resection 10 24 7 17
Radiotherapy (RT)
No 20 49 30 73
Y e s 2 15 11 02 4
U n k n o w n 0012
RT dose (Gy)
Median (range) 66 (64–74) 69 (40–72)
Chemotherapy (CT)
No 40 98 30 73
Yes 1 2 10 24
U n k n o w n 0012
CT duration (months)
Median (range) 3.7 (1.8–5.0)
Radiotherapy only 20 49 7 17
Chemotherapy only 0 0 7 17
Paclitaxel + gemcitabine 1
Paclitaxel + liposomal doxorubicin 3
Methotrexate 1
Missing data 2
S u r g e r y o n l y 1 94 61 94 6
Chemoradiotherapy 1 2 3 7
Paclitaxel + gemcitabine 1
Paclitaxel + liposomal doxorubicin 1
Missing data 1
only 10 months, while high VEGF-D with a median R-PFS
of 47 months (Figure 3).
3.5. Predictive Signiﬁcance for R-OS. Among all studied
biomarkers, only VEGF-C tumoural transcription at recur-
rence exhibited a trend for a statistically signiﬁcant associa-
tion with survival of relapsed patients (log-rank, P = .076).
Those patients who harboured tumours with high VEGF-C
at relapse had a median R-OS of 22 months, whereaspatients
with low-level tumour VEGF-C had a median survival of 44
months (Figure 4). Of note, high tumour expression levels of
VEGF-D at locoregional recurrence were associated with an
improved patient outcome, albeit not statistically signiﬁcant
(log-rank, P = .15), as had been the case with R-PFS. In
cases with low tumour VEGF-D levels, the median R-OS
was only 17 months, in contrast to cases with high VEGF-D
tumourmRNAexpression,inwhichthemediansurvivalhad
not been reached yet, at a median follow-up of 52 months
(Figure 5).
4. Discussion
The impact of locoregional recurrence in patients with
HNSCC is devastating in several aspects: function, cosmesis,
quality of life, and most importantly, survival. Standard6 Journal of Oncology
Table 2: Association of VEGF-C, VEGFR1 (FLT1), and VEGFR3 (FLT4) mRNA expression with clinicopathological parameters.
VEGF-C VEGFR1 (FLT1) VEGFR3 (FLT4)
Low High P Low High P Low High P
Alcohol consumption .168 .324 .999
Low 4 (20) 9 (45) 8 (40) 5 (25) 7 (35) 6 (32)
Moderate 10 (50) 5 (25) 5 (25) 10 (50) 8 (40) 7 (37)
High 6 (30) 6 (30) 7 (35) 5 (25) 5 (25) 6 (32)
Site of relapse .009 .056 .017
Local only 17 (85) 10 (50) 17 (85) 10 (50) 18 (90) 9 (47)
Lymph nodes ± Local 3 (19) 3 (15) 2 (10) 4 (20) 1 (5) 5 (26)
Other 0 (0) 7 (35) 1 (5) 6 (30) 1 (5) 5 (26)
Size at 1st relapse .712 .110 .999
<2cm 3 (15) 4 (20) 6 (30) 1 (5) 4 (20) 3 (16)
2–4cm 10 (50) 9 (45) 11 (55) 10 (50) 11 (55) 9 (47)
>4cm 5 (25) 2 (10) 2 (10) 5 (25) 4 (20) 3 (16)
Unknown 2(10) 5 (25) 1 (5) 4 (20) 1 (5) 4 (21)
Lymph nodes at diagnosis .342 .047 .041
N0 19 (95) 16 (80) 20 (100) 15 (75) 20 (100) 14 (74)
N1-N2 1 (5) 3 (15) 0 (0) 4 (20) 0 (0) 4 (21)
Unknown 0 (0) 1 (5) 0 (0) 1 (5) 0 (0) 1 (5)
Diﬀerentiation grade at relapse .697 .697 .697
Well or moderate 14 (70) 10 (50) 14 (70) 10 (50) 14 (70) 10 (53)
Poor or undiﬀerentiated 4 (20 5 (25) 4 (20) 5 (25) 4 (20) 5 (26)
Unknown 2 (10) 5 (25) 2 (10) 5 (25) 2 (10) 4 (21)
Pack years exposure .341 .341 .751
<52.5 9 (45) 13 (65) 9 (45) 13 (65) 10 (50) 11 (58)
>52.5 11 (55) 7 (35) 11 (55) 7 (35) 10 (50) 8 (42)
Age .527 .999 .999
<65 9 (45) 12 (60) 11 (55) 10 (50) 10 (50) 10 (53)
>65 11 (55) 8 (40) 9 (45) 10 (50) 10 (50) 9 (47)
Diagnosis to recurrence interval .333 .748 .748
<12 months 6 (30) 10 (50) 7 (35) 9 (45) 9 (45) 7 (37)
>12 months 14 (70) 10 (50) 13 (65) 11 (55) 11 (55) 12 (63)
clinical and pathological factors of established prognos-
tic signiﬁcance for patient outcome have been reported:
resection margins, regional nodal metastases, advanced T
stage, high grade, and neurogenic/vessel invasion [6, 7].
Still, 20%–30% of the patients with localised T1-T2 disease
managed with negative margin resection, nodal clearance,
and postsurgery irradiation eventually recur in the neck
[1, 2]. EGFR (HER1), HER2, HER3, and HER4 transmem-
brane receptors are essential for proliferation, motility, and
invasion of the malignant cell, with the former two having
been studied more extensively. The rate of HNSCC tumours
presenting immunohistochemical (IHC) protein overexpres-
sion was found to be 80%–90% for EGFR and 4%–39%
f o rH E R 2[ 8, 9]. Although EGFR and HER2 IHC protein
expression was shown to be of prognostic value for inferior
clinical outcome, they were unreliable predictors of beneﬁt
from targeted therapeutic agents [10]. Especially EGFR is
expressed in almost all HNSCC tumours, in keeping with the
squamous cell phenotype, while its immunohistochemical
protein staining is a subjective assay lacking the dynamic
range of quantitative evaluation. EGFR and other HER
family members form heterodimers upon ligand binding
and activate intracellular signalling cascades that regulate
survival, proliferation, motility, and angiogenesis of the
malignant cell cluster. Recent large phase III trials showed
overall survival beneﬁt from the combination of the anti-
EGFR monoclonal antibody cetuximab with radiotherapy or
chemotherapyinpatientswithlocallyadvancedormetastatic
HNSCC [11, 12]. This clinical breakthrough makes impera-
tive the need for the identiﬁcation of biomarkers that would
predict tumour response or resistance to EGFR-modulating
agents.
VEGF protein overexpression assessed by IHC was found
in 90% of HNSCC tumours, associated with a 2-fold higher
riskofdeathattwoyears[13].TheﬁveVEGFligands(VEGF-
A, B, C, D, and E) interact as dimers with the three types of
VEGF receptors (VEGFR1, 2 and 3) found on endothelial
and tumour cells. Receptor homo- or heterodimerisation
initiatescomplexintracellularsignallingmechanismsleading
to formation of new tumour blood vessels (VEGFR1 andJournal of Oncology 7
Table 3: Association of mRNA expression the HER family genes with clinicopathological parameters.
EGFR HER2 HER3 HER4
Low High P Low High P Low High P Low High P
N = 21 N = 20 N = 18 N = 18 N = 21 N = 20 N = 20 N = 19
Alcohol
Consumption .577 .404 .259 .239
Low 5 (24) 8 (40) 8 (44) 5 (28) 9 (43) 4 (20) 9 (45) 4 (21)
Moderate 9 (43) 7 (35) 7 (39) 6 (33) 6 (29) 10 (50) 6 (30) 10 (53)
High 7 (33) 5 (25) 3 (17) 7 (39) 6 (29) 6 (30) 5 (25) 5 (26)
Site of relapse .999 .501 .812 .545
Local only 14 (67) 13 (65) 13 (72) 13 (72) 13 (62) 14 (70) 12 (60) 15 (79)
Lymph nodes ±
Local 3 (14) 3 (15) 2 (11) 4 (22) 4 (19) 2 (10) 3 (15) 2 (11)
Other 4 (19) 4 (20) 3 (17) 1 (6) 4 (19) 4 (20) 5 (25) 2 (11)
Size at 1st relapse .425 .256 .145 .716
<2cm 4 (19) 3 (15) 3 (17) 4 (22) 4 (19) 3 (15) 3 (15) 4 (21)
2–4cm 9 (43) 13 (65) 8 (44) 10 (56) 9 (43) 13 (66) 11 (55) 10 (53)
>4cm 5 (24) 2 (10) 5 (28) 1 (6) 6 (29) 1 (5) 5 (25) 2 (10)
Unknown 3 (14) 2 (10) 2 (11) 3 (17) 2 (10) 3 (15) 1 (5) 3 (16)
Lymph nodes at
diagnosis .999 .999 .999 .999
N0 18 (86) 18 (90) 16 (89) 16 (89) 18 (86) 18 (90) 17 (85) 17 (89)
N1-N2 2 (10) 2 (10) 2 (11) 2 (11) 2 (10) 2 (10) 2 (10) 2 (11)
Unknown 1 (5) 0 (0) 0 (0) (0) 1 (5) 0 (0) 1 (5) 0 (0)
Diﬀerentiation
grade at relapse .240 .417 .999 .448
Well or
moderate 13 (62) 12 (60) 13 (72) 9 (50) 12 (57) 13 (65) 12 (60) 13 (81)
Poor or
undiﬀerentiated 2 (10) 7 (35) 3 (17) 5 (28) 4 (19) 5 (25) 6 (33) 3 (19)
Unknown 6 (29) 1 (5) 2 (11) 4 (22) 5 (24) 2 (10) 2 (10) 3 (16)
Pack years
exposure .999 .999 .999 .205
<52.5 11 (52) 11 (55) 10 (56) 9 (50) 11 (52) 11 (55) 8 (40) 12 (63)
>52.5 10 (48) 9 (45) 8 (44) 9 (50) 10 (48) 9 (45) 12 (60) 7 (37)
Age .217 .094 .538 .752
<65 13 (62) 8 (40) 12 (67) 6 (33) 12 (57) 9 (45) 11 (55) 9 (47)
>65 8 (38) 12 (60) 6 (33) 12 (67) 9 (43) 11 (55) 9 (45) 10 (53)
Diagnosis to
recurrence Interval .530 .305 .341 .748
<12 months 7 (33) 9 (45) 9 (50) 5 (28) 10 (48) 6 (30) 9 (45) 7 (37)
>12 months 14 (67) 11 (55) 9 (50) 13 (72) 11 (52) 14 (70) 11 (55) 12 (63)
2) or lymph vessels (VEGFR3) [14]. Therapeutic agents
targeting the VEGF ligands or receptors inhibit neoplas-
tic angiogenesis, optimise remaining vasculature, decrease
interstitial ﬂuid pressure, and synergistically kill tumour
cells when given in combination with chemotherapy or
radiotherapy in preclinical models [15]. Bevacizumab, a
monoclonal antibody that binds VEGF, and tyrosine kinase
inhibitors of the VEGF receptors are currently being evalu-
ated in HNSCC patients, along with biomarkers that could
predict for beneﬁt from such targeted therapies. Seiwert et al.
recently reported that the ratio of phosphorylated VEGFR2
to total VEGFR2, measured by immunoﬂuorescence, pre-
dicts for response in patients with recurrent or metastatic
HNSCC receiving bevacizumab/erlotinib combination ther-
apy [16].
Gene transcriptional proﬁling of messenger RNA by
means of real time kRT-PCR provides a quantitative evalu-
ation method that is not aﬀected by observer variability or
the widely known IHC technique limitations. In order to
screen for molecular predictors of outcome of patients with8 Journal of Oncology
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Figure 1: Relapse-related PFS in patients with low (blue line) and
high (red line) tumour VEGF-C mRNA expression.
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Figure 2: Relapse-related PFS in patients with low (blue line) and
high (red line) tumour VEGFR3 mRNA expression.
recurrent HNSCC, we studied fresh-frozen tumours from
41 patients with locoregional recurrence of relatively low-
risk disease at presentation: the median tumour size was
2cm, 68% of cases being T1-2, 85% N0, and 61% well to
moderately well diﬀerentiated. Despite the small sample size,
transcriptional activation of the VEGF-C/VEGFR3 axis at
relapse was associated with recurrence outside the primary
site (neck nodes or soft tissues) and inferior progression-
free and overall survival from relapse at a marginal statistical
signiﬁcance. Moreover, tumours that were node-positive
(months)
168 144 120 96 72 48 24 0
P
r
o
b
a
b
i
l
i
t
y
1
0.5
0
Figure 3: Relapse-related PFS in patients with low (blue line) and
high (red line) tumour VEGF-D mRNA expression.
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Figure 4: Relapse-related OS in patients with low (blue line) and
high (red line) tumour VEGF-C mRNA expression.
at presentation had higher VEGFR1 and VEGFR3 mRNA
expressionlevelsatrelapse.Despitethepreliminarynatureof
these ﬁndings, in a small retrospective cohort, the emergence
of statistically signiﬁcant associations of angiogenesis eﬀec-
tors with outcome, in patients initially presenting with low-
risk tumours, hints for the presence of clinical signiﬁcance
and a more robust correlation, should the sample size had
been larger.
Our observation incriminating tumoural VEGF-
C/VEGFR3 signalling in nodal/soft tissue relapse and poorJournal of Oncology 9
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Figure 5: Relapse-related OS in patients with low (blue line) and
high (red line) tumour VEGF-D mRNA expression.
post-relapse outcome is in keeping with recent published
evidence. Several investigators reported association of
protein or mRNA expression of VEGF-C with lymphatic
metastases and invasion in HNSCC, gastric, prostate, and
breast cancer cell lines and small patient series [17–19].
Of note, Tanigaki et al. found tumoural VEGF-A/VEGFR1
and 2 transcription correlated to development of distant
metastases, while VEGF-C/VEGFR3 to locoregional
recurrence [20]. Moreover, O-Charoenrat et al. reported
that in contrast to other VEGF ligands, VEGF-D mRNA
was suppressed in HNSCC tumours. Preclinical data have
shown that active HER1/2 signalling upregulates VEGF-A
and C and downregulates VEGF-D transcription in lung
adenocarcinoma and HNSCC cell lines [21]. We observed
inferior R-PFS and R-OS in patients harbouring tumours
with low VEGF-D mRNA expression compared to those
with high VEGF-D, though statistical signiﬁcance was
not reached. VEGF-D may exert an antagonistic eﬀect on
neoplastic neovascularisation, forming heterodimers with
VEGF-A, B, and C and modulating the activity of the
VEGFR1, 2, and 3 along with the neuropilin receptors. This
phenomenon of counter-regulation is probably extremely
important for the ﬁne-tuning of angiogenesis. Recently,
VEGF-Ab, a splice variant of the powerful proangiogenic
VEGF-A ligand, was shown to exert antiangiogenic eﬀects in
normal tissues and a variety of solid tumours [22].
The mechanism of the adverse prognostic impact of
VEGF-C/VEGFR3 signalling may include dissemination of
tumour cells in the systemic circulation and arrest in
lymph nodes/distant sites, direct enhancement of lymph-
angiogenesis, and creation of a permissive environment for
tumour progression by the induction of adhesion molecules,
growth factors, and proteolytic enzymes. In contrast to
VEGF-C, HER signalling was not signiﬁcant for predicting
patient outcome, despite in vitro data emphasizing its key
role in the control of cell cycle, invasion, and the induction
of VEGF-A and C-mediated angiogenesis. Indeed, in an
HNSCC patient series, protein expression of EGFR or HER2
could not predict beneﬁt from chemotherapy or targeted
therapies [8–11]. Only EGFR gene ampliﬁcation activating
EGFRgenemutationsandthepresenceofthetruncatedform
of the EGFRvIII protein correlated with clinical beneﬁt or
patient outcome [10]. Although our mRNA methodology
could not screen for these biomarkers, Agulnik et al. found
excess EGFR gene copy numbers in only 4 out of 37 patients,
and Willmore-Payne et al. reported HER1/2 mutations
in less than 10% of patients with HNSCC [23, 24]. In
contrast, Chung et al. observed EGFR gene ampliﬁcation
in 58% of 75 recurrent or metastatic HNSCC patients and
reported its association with poor outcome [25]. However,
EGFR copy number status did not correlate with protein
or mRNA expression. This could explain our inability to
ﬁnd any prognostic signiﬁcance for EGFR mRNA levels in
our study. Indeed, HER1/HER2 gene ampliﬁcation may be
an early oncogenic event, with most gene copies becoming
transcriptionally inactive later. Alternate splicing of EGFR
transcripts, not detected by our mRNA probes, could also
oﬀer another explanation [26]. Moreover, the EGFR/HER2
genes may carry prognostic information not associated with
their ampliﬁcation status per se but rather act as surrogate
markers of genetic instability or of other coampliﬁed genes
[27]. Of note, Seiwert et al. reported that endothelial but not
tumour cell EGFR protein levels correlated with response to
bevacizumab + erlotinib [16]. Moreover, the combination
reduced VEGFR2 and EGFR protein expression in neoplastic
endotheliabutnottumourcells.OurmRNAanalysis,though
b a s e do nf r o z e ns e c t i o n sw i t h≥70% tumour cellularity,
would not discriminate between tumour cells and neoplastic
vessel endothelial cells.
In conclusion, VEGF-C/VEGFR3 mRNA expression at
relapsemaybeofpotential valueasanewbiomarkerpredict-
ing nodal/soft tissue regional relapse and poor outcome after
recurrence in HNSCC patients. It should be stressed that
molecular proﬁling of primary tumours is necessary in order
to obtain prognostic information at diagnosis. Comparison
of the molecular proﬁles of primary and matched recurrent
tumors is required to derive safe conclusions and was not
doneinourstudy.Still,ourﬁndingsmayserveashypothesis-
generating data and, if validated in larger prospective series,
may justify more aggressive neck management at presen-
tation and treatment of HNSCC patients exhibiting high
VEGF-C mRNA expression with targeted therapies (anti-
VEGF-C antibodies, VEGFR3 tyrosine kinase inhibitors),
either upfront or at recurrence, in order to optimise their
outcome.
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